ONESOURCE Q1 FY27 results at a glance
ONESOURCE SPECL PHARMA L Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹449 cr |
|---|
| Revenue YoY | +37.2% |
|---|
| Operating profit | ₹51.6 cr |
|---|
| Operating margin | 11.5% |
|---|
| Net profit | ₹25 cr |
|---|
| Net profit YoY | +13539.2% |
|---|
| Net profit QoQ | +443.8% |
|---|
| Net margin | 5.6% |
|---|
| Basic EPS | ₹2.18 |
|---|
| TTM revenue | ₹1,543 cr |
|---|
| TTM net profit | -₹48.62 cr |
|---|
| TTM net margin | -3.2% |
|---|
ONESOURCE Q1 FY27 results: what the numbers say
ONESOURCE SPECL PHARMA L (ONESOURCE) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹449 cr and a net profit of ₹25 cr, translating into earnings per share of ₹2.18.
Compared with the same quarter a year earlier, revenue grew strongly by +37.2% and net profit grew sharply by +13539.2%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹51.6 cr, an operating margin of 11.5% versus 6.3% a year ago — a gain of 5.2 percentage points.
ONESOURCE quarter-wise results table
Net profit
₹25 cr
+13539.2% YoY
Operating profit
₹51.6 cr
+149.5% YoY
ONESOURCE SPECL PHARMA L (ONESOURCE) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹449 cr | ₹51.6 cr | ₹25 cr | 11.5% | 5.6% | ₹2.18 | +13539.2% | +443.8% |
| Q4 FY262026-03-31 | ₹428 cr | ₹20.1 cr | ₹4.6 cr | 4.7% | 1.1% | ₹0.40 | — | +105.2% |
| Q3 FY262025-12-31 | ₹290 cr | -₹52.32 cr | -₹88.7 cr | -18.0% | -30.6% | ₹-7.74 | — | -946.0% |
| Q2 FY262025-09-30 | ₹376 cr | ₹36.67 cr | ₹10.49 cr | 9.8% | 2.8% | ₹0.92 | — | +5737.1% |
| Q1 FY262025-06-30 | ₹327 cr | ₹20.68 cr | -₹0.19 cr | 6.3% | -0.1% | ₹-0.02 | — | — |
| TTM (last 4 quarters) | ₹1,543 cr | ₹56.05 cr | -₹48.62 cr | 3.6% | -3.2% | ₹-4.24 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
ONESOURCE quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
ONESOURCE SPECL PHARMA L quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹449 cr | ₹428 cr | ₹290 cr | ₹376 cr | ₹327 cr |
|---|
| Total expenses | ₹397 cr | ₹408 cr | ₹343 cr | ₹339 cr | ₹307 cr |
|---|
| Gross profit | ₹307 cr | ₹282 cr | ₹196 cr | ₹262 cr | ₹234 cr |
|---|
| Operating profit (EBIT) | ₹51.6 cr | ₹20.1 cr | -₹52.32 cr | ₹36.67 cr | ₹20.68 cr |
|---|
| Operating margin | 11.5% | 4.7% | -18.0% | 9.8% | 6.3% |
|---|
| Interest cost | ₹30.81 cr | ₹22.51 cr | ₹38.23 cr | ₹33.96 cr | ₹27.48 cr |
|---|
| Profit before tax | ₹20.29 cr | -₹0.29 cr | -₹93.01 cr | ₹5.74 cr | -₹4.4 cr |
|---|
| Tax expense | -₹4.7 cr | -₹4.89 cr | -₹4.31 cr | -₹4.74 cr | -₹4.21 cr |
|---|
| Effective tax rate | -23.2% | 1674.3% | 4.6% | -82.6% | 95.8% |
|---|
| Net profit (PAT) | ₹25 cr | ₹4.6 cr | -₹88.7 cr | ₹10.49 cr | -₹0.19 cr |
|---|
| Net profit margin | 5.6% | 1.1% | -30.6% | 2.8% | -0.1% |
|---|
| Basic EPS | ₹2.18 | ₹0.40 | ₹-7.74 | ₹0.92 | ₹-0.02 |
|---|
| Diluted EPS | ₹2.18 | ₹0.40 | ₹-7.74 | ₹0.91 | ₹-0.02 |
|---|
ONESOURCE results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +37.2% | — | — | — | — |
|---|
| Revenue QoQ | +4.9% | +47.5% | -22.7% | +14.8% | — |
|---|
| Operating profit YoY | +149.5% | — | — | — | — |
|---|
| Operating profit QoQ | +156.8% | +138.4% | -242.7% | +77.3% | — |
|---|
| Net profit YoY | +13539.2% | — | — | — | — |
|---|
| Net profit QoQ | +443.8% | +105.2% | -946.0% | +5737.1% | — |
|---|
| EPS YoY | +11000.0% | — | — | — | — |
|---|
| EPS QoQ | +445.0% | +105.2% | -941.3% | +4700.0% | — |
|---|
ONESOURCE annual results history
Full-year performance for ONESOURCE SPECL PHARMA L, useful for reading each quarter in context.
ONESOURCE SPECL PHARMA L annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹1,422 cr | ₹1,445 cr | ₹172 cr | ₹38.71 cr |
|---|
| Total expenses | ₹1,427 cr | ₹1,254 cr | ₹328 cr | ₹255 cr |
|---|
| Gross profit | ₹977 cr | ₹1,010 cr | ₹101 cr | ₹18.3 cr |
|---|
| Operating profit (EBIT) | -₹5.47 cr | ₹190 cr | -₹157 cr | -₹216 cr |
|---|
| Operating margin | -0.4% | 13.2% | -91.0% | -557.6% |
|---|
| Interest cost | ₹111 cr | ₹154 cr | ₹85.4 cr | ₹40.11 cr |
|---|
| Profit before tax | -₹91.96 cr | -₹67.07 cr | -₹366 cr | -₹416 cr |
|---|
| Tax expense | -₹18.16 cr | -₹49.79 cr | ₹0 cr | ₹0 cr |
|---|
| Effective tax rate | 19.7% | 74.2% | 0.0% | 0.0% |
|---|
| Net profit (PAT) | -₹73.8 cr | -₹17.97 cr | -₹391 cr | -₹800 cr |
|---|
| Net profit margin | -5.2% | -1.2% | -227.5% | -2066.0% |
|---|
| Basic EPS | ₹-6.44 | ₹-1.63 | ₹-34.18 | ₹-69.89 |
|---|
| Diluted EPS | ₹-6.44 | ₹-1.63 | ₹-34.18 | ₹-69.89 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹449 cr against ₹327 cr in Q1 FY26, and ₹428 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +4.9%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹397 cr, or 88.5% of revenue, with operating profit grew +149.5% year on year.
Margins, tax and profitability
Net profit of ₹25 cr works out to a net margin of 5.6% compared with -0.1% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, ONESOURCE SPECL PHARMA L reported profit before tax of ₹20.29 cr, a tax charge of -₹4.7 cr (effective rate -23.2%), interest cost of ₹30.81 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹4.6 cr in Q4 FY26 to ₹25 cr in Q1 FY27, a change of +443.8%.
Trailing twelve months and annual context
Across the trailing four quarters ONESOURCE SPECL PHARMA L has generated revenue of ₹1,543 cr and net profit of -₹48.62 cr, a trailing net margin of -3.2%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹1,422 cr with net profit of -₹73.8 cr and EPS of ₹-6.44, versus the prior year where revenue declined -1.6% and profit declined -310.7%.
What to watch in the next ONESOURCE quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
ONESOURCE SPECL PHARMA L has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
ONESOURCE results coverage
No results report published for ONESOURCE yet — our desk covers each quarter within minutes of the filing.
ONESOURCE quarterly results FAQs
What were ONESOURCE SPECL PHARMA L (ONESOURCE) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), ONESOURCE SPECL PHARMA L reported revenue of ₹449 cr and net profit of ₹25 cr, a change of +13539.2% year on year on +37.2% revenue growth. EPS stood at ₹2.18.
What is ONESOURCE profit margin in Q1 FY27?
ONESOURCE SPECL PHARMA L posted a net profit margin of 5.6% and an operating margin of 11.5% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹1,543 cr and net profit -₹48.62 cr.
Did ONESOURCE results beat the previous quarter?
ONESOURCE SPECL PHARMA L net profit changed +443.8% quarter on quarter, from ₹4.6 cr in Q4 FY26 to ₹25 cr in Q1 FY27.
When are ONESOURCE SPECL PHARMA L (ONESOURCE) quarterly results?
ONESOURCE SPECL PHARMA L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see ONESOURCE latest quarterly results?
Results coverage for ONESOURCE will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the ONESOURCE stock page.
What is ONESOURCE SPECL PHARMA L annual revenue and profit?
For FY26, ONESOURCE SPECL PHARMA L reported full-year revenue of ₹1,422 cr and net profit of -₹73.8 cr, with EPS of ₹-6.44.
How many quarterly results has ONESOURCE declared recently?
Past results dates for ONESOURCE will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
